

# **A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)**

Tower Hematology Oncology Medical Group, Beverly Hills, California, United States

UCSF MS Center, San Francisco, California, United States

University of Colorado Health Science Center - Aurora, Aurora, Colorado, United States

Yale University School of Medicine, New Haven, Connecticut, United States

Northwest Oncology Hematology Associates PA, Coral Springs, Florida, United States

Emory University Medical Genetics, Decatur, Georgia, United States

Children's Memorial Hospital, Chicago, Illinois, United States

University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

Albany Medical Center, Albany, New York, United States

North Shore University Medical Center, Manhasset, New York, United States

Mount Sinai School of Medicine, New York, New York, United States

New York University School of Medicine, New York, New York, United States

Duke University Medical Center, Durham, North Carolina, United States

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

O and O Alpan LLC, Springfield, Virginia, United States

Hospital General de Agudos J.M Ramos Mejia, Buenos Aires, , Argentina

Hospital General de Niños Dr. Ricardo Gutierrez, Buenos Aires, , Argentina

Royal Perth Hospital, Perth, WA, , Australia

Hospital de Clinicas da Universidade Federal do Parana, Curitiba, , Brazil

Instituto de Estadual de Hematologia Arthur de Siqueira Cavalcanti, Rio de Janeiro, , Brazil

IGEIM, São Paulo, , Brazil

Mount Sinai Hospital and the Samuel Lunenfeld Research Institute, Toronto Ontario, , Canada

Abou El Reesh Children's University Hospital (El Mounira), Faculty of Medicine (Kasr Al-Aini), Cairo University

Hôpital Beaujon, Clichy, , France

Charité Universitätsmedizin Berlin, Berlin, , Germany

Asklepios Klinik St. Georg, Hamburg, , Germany

Katholische Kliniken Oberhausen gem. GmbH, Oberhausen, , Germany

Azienda Ospedaliero Universitaria Careggi, Firenze, , Italy

Azienda Ospedaliero-Universitaria S. Maria Della Misericordia, Udine, , Italy

Hematology Research Center of Ministry of Healthcare of the Russian Federation, Moscow, , Russian Federation

Hospital University Miguel Servet, Zaragoza, , Spain

Cambridge University Hospitals, Addenbrookes Hospital, Cambridge, , United Kingdom

This Phase 3 study was designed to confirm the efficacy and safety of eliglustat tartrate

(Genz-112638) in participants with Gaucher disease type 1 who had reached therapeutic goals with enzyme replacement therapy (ERT).